Open for inclusion

A Phase II randomized, douple-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breats cancr subjects with bone metastases treated with hormonl treatment backgro

Cancer type: Breast cancer

Phase: II

Principal Investigator: Mattson Johanna

Country: FI

Keywords: Finland, Helsinki

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02258464